^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Marginal Zone Lymphoma
    Drug:parsaclisib (INCB50465) (PI3Kδ inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    Incyte Press Release
    Title:

    Incyte Announces Acceptance of NDA for Parsaclisib for Three Types of Relapsed or Refractory Non-Hodgkin Lymphomas

    Published date:
    11/01/2021
    Excerpt:
    Parsaclisib has been granted Priority Review by the FDA for the treatment of adult patients with relapsed or refractory MZL who have received at least one prior anti-CD20-based regimen and for the treatment of adult patients with MCL who have received at least one prior therapy.